Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, Alucent Biomedical is raising $34,999,999.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Myles Greenberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alucent Biomedical

Alucent Medical, Inc. is a privately-held biotechnology company, based in Salt Lake City, UT, developing a novel drug-device combination therapy, Natural Vascular Scaffolding (NVS) for patients with peripheral vascular disease. The photoactivated vessel-restoring power of NATURAL VASCULAR SCAFFOLDING designed to durably open without implants.

To learn more about Alucent Biomedical, visit http://alucentmedical.com/

Contact:
Myles Greenberg, President and Chief Executive Officer
385-722-2300
https://www.linkedin.com/in/mylesgreenberg/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved